Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors

Cytotherapy - Tập 13 - Trang 92-97 - 2011
Atsutaka Noguchi1,2, Toru Kaneko1, Takashi Kamigaki1, Katsunada Fujimoto1, Masanori Ozawa1, Masashi Saito1, Naoko Ariyoshi2, Shigenori Goto1
1Seta Clinic Group, Tokyo, Japan
2Medinet Medical Institute, Medinet Co. Ltd, Tokyo, Japan

Tài liệu tham khảo